Medical Library | Shanghai Oncology and Innovative Treatment Series
Shanghai's cancer-care landscape extends well beyond its largest specialty centers. A number of teams at general hospitals, surgical hospitals, and research institutes are advancing remote robotic surgery, translational microbiome research, complex head-and-neck oncology, single-port thoracic procedures, breast reconstruction, and cancer biology.
This Medical Library review summarizes six additional teams and programs with reported 2025–2026 progress. The focus is on what each development may mean clinically, while keeping a clear distinction between a completed procedure, a research project, a published mechanism, and a treatment that is routinely available to patients.
1. Shanghai Tenth People's Hospital: 5G Remote Robotic Surgery for Kidney Cancer
Team: Urology, led by Professor Shen Bing
Reported milestone: In June 2026, the team completed what was described as Tibet's first 5G remote robot-assisted radical kidney cancer surgery across a distance of 4,382 kilometers.
Remote robotic surgery aims to connect specialist surgical expertise with patients in regions where complex procedures may not be locally available. The technical achievement depends on low-latency communication, reliable imaging, robotic-system safety, local anesthesia and operating-room teams, and a clear plan for managing emergencies if the connection is interrupted.
For patients, the most important question is not simply whether a procedure was performed remotely. It is whether remote surgery is appropriate for the tumor's anatomy and stage, whether the local team can provide perioperative and postoperative care, and how complications would be managed. Our Urologic Cancers and Conditions Treatment in Shanghai guide provides related background for patients considering specialist urologic care.
Why it matters: The program demonstrates how 5G and robotics may extend specialist surgical capabilities across geographic boundaries.
2. Tongji Hospital: A Natural Products, AI, Synthetic Biology, and Microbiome Platform
Team: General Surgery, led by Professor Li Xinxing
Reported milestone: In March 2026, the team received a RMB 4 million research grant to build an integrated program covering natural products, artificial intelligence, synthetic biology, and the microbiome in radiation enteritis and inflammatory bowel disease.
Radiation enteritis and inflammatory bowel disease can involve overlapping symptoms but require different diagnostic and treatment strategies. A cross-disciplinary platform may help researchers identify bioactive compounds, model disease mechanisms, analyze patient data, and explore microbiome-based interventions.
The value of this type of project will depend on how well it moves from data and laboratory discovery into validated biomarkers, safe interventions, and prospective clinical studies. Patients should be cautious about commercial products that claim to “rebalance” the microbiome without clinical evidence in the specific disease.
Why it matters: The project links natural-product discovery with computational analysis, synthetic biology, and microbiome research instead of treating these as separate fields.
3. Shanghai Ninth People's Hospital: Conversion Treatment and Radical Surgery for Advanced Tongue Cancer
Team: Oral and maxillofacial–head and neck oncology multidisciplinary team
Reported milestone: In January 2026, the team completed radical surgery after conversion treatment for a patient with extremely advanced tongue cancer. The National Center for Stomatology was also established in Pudong.
Advanced tongue cancer often requires coordination among head-and-neck surgeons, medical oncologists, radiation oncologists, reconstructive surgeons, dentists, speech and swallowing specialists, and nutrition teams. Conversion treatment is intended to reduce or control disease sufficiently to make a previously difficult operation possible.
Conversion treatment does not guarantee that surgery will be appropriate. The decision depends on response, imaging, tumor invasion, distant disease, the patient's nutritional and functional status, and whether a complete resection with acceptable quality of life is realistic. Functional outcomes such as speech, swallowing, airway protection, and reconstruction are as important as the operation itself.
Why it matters: The case illustrates how multidisciplinary treatment may create a surgical opportunity in selected patients with extremely advanced disease, while the new national center strengthens the region's oral and maxillofacial oncology infrastructure.
4. Xinhua Hospital: Bringing Complex Thoracic Techniques into Broader Practice
Team: Cardiothoracic surgery and respiratory medicine, led by Professors Liang Zhigang and Chen Zhihong
Reported progress: The team is advancing post-neoadjuvant single-port thoracoscopic bronchial sleeve resection and microwave ablation for selected small lung nodules.
Bronchial sleeve resection can preserve more lung tissue than removing an entire lung in appropriately selected patients, but it requires precise tumor assessment, airway reconstruction, and careful perioperative management. Performing the operation after neoadjuvant treatment adds another layer of complexity because treatment may alter tissue planes, inflammation, and surgical risk.
Microwave ablation may be considered for selected small lung nodules when surgery is not the best option or when a less-invasive local treatment is appropriate. It is not interchangeable with surgical resection for every patient. Tumor location, pathology, size, pulmonary function, prior treatment, and the risk of local recurrence all need to be reviewed.
Our Lung Cancer and Advanced Oncology Treatment in Shanghai article and Lung Cancer Precision Diagnosis and Rapid Treatment Planning guide may help patients prepare questions about surgery, ablation, and multimodal treatment.
Why it matters: The program reflects the effort to make advanced thoracic techniques and local treatment options more accessible beyond a small number of highly concentrated centers.
5. Shanghai Sixth People's Hospital: Endoscopic Breast Reconstruction with a Pedicled Omental Flap
Team: Thyroid, breast, and hernia surgery, led by Professor Lu Lingli
Reported milestone: In August 2026, the Lingang campus completed its first endoscopic breast reconstruction using a pedicled greater-omentum flap after breast cancer surgery.
A pedicled omental flap uses vascularized tissue from the greater omentum to help reconstruct the breast. An endoscopic approach aims to reduce the size and visibility of incisions in selected patients, but the correct reconstructive option depends on tumor treatment, body habitus, prior surgery, abdominal anatomy, and patient preference.
Breast reconstruction should be discussed as part of the cancer-treatment plan, not as an isolated cosmetic procedure. Patients should ask how reconstruction may affect radiotherapy, wound healing, future imaging, symmetry, abdominal recovery, and the timing of any additional surgery. Our Breast Cancer Treatment in Shanghai Medical Library guide offers broader treatment context.
Why it matters: The procedure expands the range of reconstructive options available to selected breast cancer patients while combining minimally invasive access with autologous tissue reconstruction.
6. Shanghai Institute of Oncology: Cancer Biology from Metabolism to Neural Interactions
Teams: Research groups led by Tu Hong and Gan Yu, Jin Haojie, and Zhang Zhigang
Reported areas of progress:
- A Cell Metabolism study in December 2025 examining calorie restriction and anti-cancer mechanisms;
- A Science Translational Medicine cover study in February 2025 addressing toxicity associated with CAR-T-mediated tumor clearance;
- A Neuron study in April 2026 examining neural interactions in pancreatic cancer.
These programs address different layers of cancer biology. Metabolic research examines how nutrient availability and systemic metabolism may influence tumor growth. CAR-T toxicity research explores how the immune response and rapid tumor elimination can produce serious clinical effects. Neural-interaction research investigates how nerves and tumor cells may influence one another in the pancreatic tumor microenvironment.
Such studies may eventually lead to new treatment targets or safety strategies, but publication in a high-impact journal does not mean that a corresponding therapy is already available. Patients should ask whether a finding has moved into a validated biomarker, a clinical test, or a human trial.
Why it matters: The institute demonstrates how metabolism, cellular therapy safety, and tumor–nerve biology are expanding the scientific framework for cancer treatment.
7. How to Read These Developments as a Patient
The six programs represent different types of progress:
- Clinical technology: remote robotic surgery, sleeve resection, microwave ablation, and endoscopic reconstruction.
- Multidisciplinary treatment: conversion therapy and radical surgery for advanced tongue cancer.
- Translational platforms: natural products, AI, synthetic biology, and microbiome research.
- Basic cancer biology: metabolism, CAR-T toxicity, and neural interactions in tumors.
Before making a treatment decision, patients should distinguish between a reported technical milestone, a single successful procedure, a research grant, a published mechanism, a clinical trial, regulatory approval, and routine standard care. The best next step depends on the patient's diagnosis, stage, pathology, imaging, previous treatment, organ function, and personal goals.
8. How CMCS Helps International Patients Communicate with Specialists
For an international patient considering surgery, an advanced local treatment, or a research-based therapy in Shanghai, the most useful first step is to bring complete information to the appropriate specialist team. China Medical Concierge Shanghai (CMCS) is a health management and medical coordination service that helps patients connect with specialist doctors and hospital resources in Shanghai. CMCS is not a hospital and does not independently diagnose or prescribe treatment.
Before a consultation, CMCS can help organize pathology reports, imaging, operative notes, endoscopy or bronchoscopy records, laboratory results, previous treatments, medication history, current symptoms, and the patient's questions. For overseas patients, these records can be arranged into a concise English medical summary for the specialist.
CMCS can help patients prepare focused questions such as:
- Is the proposed operation or technology appropriate for this tumor's location, stage, and anatomy?
- Is the treatment established standard care, a specialized procedure, or part of a clinical trial?
- What evidence supports the proposed approach, and what are the realistic benefits and risks?
- For remote surgery, what local backup and emergency plan are in place?
- For advanced cancer, has the disease responded sufficiently for conversion surgery, and what are the functional consequences?
- For a microbiome, AI, or molecular program, is the test or intervention clinically validated?
- What alternatives should be considered, and how will recovery and follow-up be managed?
During the consultation, CMCS can assist with appointment coordination, medical interpretation, communication between the patient and the care team, and clarification of the doctor's recommendations. Afterward, a case manager can help organize the proposed next steps, identify additional tests or records, clarify the follow-up schedule, and coordinate further communication with the hospital.
The final treatment decision must be made by the patient and the treating medical team. CMCS does not independently select an operation, device, drug, or research program. Its role is to help the patient bring complete information to the right specialist and ensure that evidence, risks, alternatives, access, and monitoring are discussed clearly.
To learn more about oncology consultations and treatment coordination in Shanghai, contact CMCS:
Email: contract@medicalsh.com
WhatsApp: Contact CMCS on WhatsApp
Website: medicalsh.com
Conclusion
These additional Shanghai teams show how cancer care is advancing not only through blockbuster medicines, but also through surgical engineering, remote connectivity, reconstruction, multidisciplinary conversion treatment, microbiome platforms, and fundamental cancer biology.
For patients, the goal is not to pursue every new technology, but to determine which evidence-based option fits the diagnosis, stage, biology, previous treatment, health status, and personal priorities. This article was prepared from the team and program information provided for editorial use. Research milestones, clinical availability, and treatment recommendations should be confirmed through the hospital, research team, regulatory authorities, and formally published studies. This article is for medical education only and is not individualized medical advice.
0 comments